Orally administered, insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats

C T Musabayane1, O Munjeri2, P Bwititi1 and E E Osim1
1Department of Physiology, University of Zimbabwe, P O Box MP167, Mount Pleasant, Harare, Zimbabwe
2Department of Pharmacy, University of Zimbabwe, P O Box MP167, Mount Pleasant, Harare, Zimbabwe

(Requests for offprints should be addressed to C T Musabayane; Email: ctm@kidney.uZ.zw or Musabayane@mango.apc.org.zw)

Abstract

We report successful oral administration of insulin entrapped in amidated pectin hydrogel beads in streptozotocin (STZ)-diabetic rats, with a concomitant reduction in plasma glucose concentration. The pectin–insulin (PI) beads were prepared by the gelation of humulin–pectin solutions in the presence of calcium. Separate groups of STZ-diabetic rats were orally administered two PI beads (30 µg insulin) once or twice daily or three beads (46 µg) once daily for 2 weeks. Control non-diabetic and STZ-diabetic rats were orally administered pectin hydrogel drug-free beads. By comparison with control non-diabetic rats, untreated STZ-diabetic rats exhibited significantly low plasma insulin concentration (0·32 ± 0·03 ng/ml, n=6, compared with 2·60 ± 0·44 ng/ml in controls, n=6) and increased plasma glucose concentrations (25·84 ± 1·44 mmol/l compared with 10·72 ± 0·52 mmol/l in controls). Administration of two PI beads twice daily (60 µg active insulin) or three beads (46 µg) once a day to STZ-diabetic rats increased plasma insulin concentrations (0·89 ± 0·09 ng/ml and 1·85 ± 0·26 ng/ml, respectively), with a concomitant reduction in plasma glucose concentration (15·45 ± 1·63 mmol/l and 10·56 ± 0·26 mmol/l, respectively). However, a single dose of PI beads (30 µg) did not affect plasma insulin concentrations, although plasma glucose concentrations (17·82 ± 2·98 mmol/l) were significantly reduced compared with those in untreated STZ-diabetic rats. Pharmacokinetic parameters in STZ-diabetic rats show that the orally administered PI beads (30 µg insulin) were more effective in sustaining plasma insulin concentrations than was s.c. insulin (30 µg). The data from this study suggest that this insulin-loaded amidated pectin hydrogel bead formulation not only produces sustained release of insulin, but may also reduce plasma glucose concentration in diabetes mellitus.

Introduction

Treatment of diabetes mellitus usually requires daily s.c. injections of insulin, which can result in non-compliance of the patient because of local discomfort caused and inconvenience of multiple administration (Van Haefen et al. 1987). The oral route is the most acceptable route of administration of insulin and may thus encourage patient compliance. However, oral administration of insulin is precluded by digestion in the stomach and small intestine (Lee et al. 1991, Zhou & Li Wan Po 1991). Schilling & Mitra (1990) have suggested that delivery to the mid-jejunum protects insulin from hydrolysis and that release from the dosage form is enhanced by intestinal microflora. The need to find a system for oral administration of insulin has resulted in many investigations to protect the molecule from degradation and to facilitate transepithelial transport of the intact molecule (Saffran et al. 1986, 1990).

Attempts have been made to deliver insulin to the more distal portions of the gastrointestinal tract by microencapsulation using Eudragit RS 100 (Morishita et al. 1993). Polymeric structures formed by polymerization of isobutyl cyanocrylate (IBCA) in an acidic medium have also been used for oral administration of insulin in diabetic rats (Damge et al. 1997). However, the limitations of these formulations include the difficulty of removing organic solvents from the final product and the possibility of structural modification of the drug. Pectin (polygalacturonic acid) has been investigated for specific delivery to the colon because it is biodegradable (Ashford et al. 1993, Rubinstein et al. 1993, Munjeri et al. 1998(a, b)). Colonic release of insulin by a pectin-coated support has already been examined (Rubinstein et al. 1997). The purpose of the present study was to investigate the effects of oral administration of insulin-loaded amidated pectin beads on plasma insulin and plasma glucose in streptozotocin (STZ)-diabetic rats.
Materials and Methods

Chemicals

Streptozotocin, calcium chloride, monobasic potassium phosphate, pancreatin and pepsin were obtained from Sigma Chemical Company (St Louis, MO, USA), humilin (Isophane Human Insulin manufactured by Lilly France SA, Fegershiem, France) was obtained from Eli Lilly, Pty Ltd (Isando, Guateng, Republic of South Africa). Sodium hydroxide, potassium hydroxide and chloroform were obtained from Associated Chemical Enterprises (Mulbarton, Republic of South Africa). Hydrochloric acid (HCl, 32% v/v) was obtained from Saarchem Muldedrift (Krugersdorp, Republic of South Africa). Amidated low-methoxyl pectin with a degree of methoxylation of 23 and amidated pectin–insulin hydrogel beads

Preparation of pectin–insulin hydrogel beads

The method of hydrogel bead production was similar to that reported previously (Munjeri et al. 1997, 1998). Pectin solutions (4% w/v) were prepared by dispersing the pectin powder in distilled water with the aid of a high-speed mixer. Amidated pectin–insulin (PI) hydrogel beads with specified pectin : humilin (v/v) ratios of 200 : 1, 133 : 1 and 80 : 1 were produced by dispersing insulin-loaded amidated pectin solutions drop-wise into 300 ml agitated calcium chloride 2% (w/v) solutions. The solutions were pumped at 1-0 ml/min by a peristaltic pump (Masterflex, Barrington, IL, USA) through a tube 2 mm in diameter. The beads were separated and dried thoroughly in air and stored in the refrigerator until use. Insulin loading efficiencies were determined by radioimmunoassay after a specified number of beads were completely dissolved in Sorensen’s phosphate buffer (pH 7-4). Preliminary studies showed that amidated pectin beads with 80 : 1 humilin loading were appropriate for using in the animals.

Animal studies

Male Sprague–Dawley rats (230–260 g body weight), bred and housed in the Medical Faculty animal house of the University of Zimbabwe, were made diabetic by an i.p. injection of STZ 60 mg/kg-1 in citrate buffer. Vehicle-injected animals acted as non-diabetic controls. Animals that exhibited glycosuria after 24 h, tested by the combor 9 test (Boehringer) were considered diabetic. The rats were kept separately in metabolism cages (NKP, Dartford, Kent, UK) that were cleaned daily. Four groups of STZ-diabetic rats and an additional group of non-diabetic rats were used. One group was orally administered two PI beads (30 µg insulin) once daily at 0900 h and the second group received the same dose of PI beads at 0900 h, followed by the same dose 8 h later (1700 h). The third group of STZ-diabetic rats was orally administered PI beads (46 µg) daily for 2 weeks at 0900 h. Untreated STZ-diabetic and control non-diabetic rats were orally administered pectin hydrogel drug-free beads. The beads were administered by means of a soft tube and complete delivery to the stomach was achieved by flushing the beads with 1 ml water.

The rats in all groups had both food (Mouse Compriods, National Foods, Harare, Zimbabwe) and water available ad libitum; amounts consumed and body weights were measured daily for 2 weeks. Urine volumes voided and fluid and food consumption were determined at 0900 h each day. After 2 weeks, blood samples were collected at 0900 h into plain tubes (for insulin measurements) and fluoride tubes (for glucose determinations). Plasma was separated by centrifugation at 3000 r.p.m. (Sorvall RT6000 refrigerated centrifuge, Dupont, Boston, MA, USA) for 10 min. Plasma for measurement of insulin was stored in a Bio Ultra freezer (Mallinckrodt, Ohio, USA) at −70 °C until required for measurements of insulin by radioimmunoassay.

Pharmacokinetic studies

Separate groups of STZ-diabetic rats previously given two beads (30 µg insulin) at 0900 h and the same dose at 1700 h were used for pharmacokinetic studies. Sixteen hours after the last dose, the animals were administered either PI beads (30 µg insulin) orally, or s.c. insulin (30 µg) at 0900 h, followed by a similar dose at 1700 h. Blood samples were collected for insulin and glucose measurements at 0900 h, 1100 h, 1300 h, 1700 h, 1500 h and 2100 h, and at 0300 h on the following day.

Plasma glucose and serum insulin measurements

Plasma glucose concentrations were measured by the glucose oxidase method immediately after collection using a Glucose Enzymatique Kit from bioMérieux SA (Marcy-l’Etoile, France). Serum insulin concentrations were measured by Coat-A-Count procedure using a kit from Diagnostic Products Corporation (Los Angeles, CA, USA). This is a solid-phase radioimmunoassay procedure based on insulin-specific antibody immobilized to the wall of a polypropylene tube. The lower limit of detection was 55 pg/ml. Inter- and intra-assay coefficients of variation were 8-1% (n=20) and 8-3% (n=20) respectively.

Data analysis

All data were subjected to one-way analysis of variance; Scheffé’s multiple comparison test was used to resolve any apparent differences. A value of P>0-05 was considered significant. The time for the peak insulin plasma

Journal of Endocrinology (2000) 164, 1–6

Downloaded from Bioscientifica.com at 12/05/2018 01:14:26PM via free access
concentration \( (T_0) \) and the maximum plasma insulin concentrations \( (C_{\text{max}}) \) were obtained from the graph. The area under the curve up to the last sampling time after the oral dose or s.c. insulin injection was calculated by the trapezoidal rule. The remaining area was calculated using the formula \( Cx/kef \) (Cx being the last plasma concentration determined and kef the slope of the terminal part of the graph). The loading efficiency of the beads was calculated by dividing the actual insulin content in the beads by the theoretical content and expressed as a percentage.

**Results**

**Insulin-loading efficiency in the pectin hydrogel beads**

The loading efficiency of insulin in beads ranged from 74 to 85% (Table 1) and each bead made from the solution with a pectin : insulin ratio of 80:1 contained 15 \( \mu \)g insulin. A minimum dose of 30 \( \mu \)g insulin was selected for the in vivo studies and compares to doses previously used in other studies (Shaw & Su 1991, Sai et al. 1996).

**Water and electrolyte turnover in 2 weeks**

Table 2 compares 24h food intake, daily weight changes and volumes of urine voided by control non-diabetic and STZ-diabetic rats and treated STZ-diabetic rats. Untreated non-diabetic rats progressively gained weight, whereas STZ-diabetic animals lost weight throughout the 10-day period, before gaining between 12 and 14 days. The total amount of food consumed by non-diabetic and untreated STZ-diabetic rats did not differ significantly. However, daily oral administration of PI beads reduced the amount of food consumed between days 6 and 10, before returning to values comparable to those in untreated non-diabetic and diabetic rats during days 12 and 14. Untreated STZ-diabetic animals consumed more water throughout the 2-week period compared with other groups. The water intake by treated diabetic rats did not

---

**Table 1** Insulin-loading efficiencies in bead samples. Each theoretical and actual loading value represents the mean value of five different samples, with each sample containing five beads.

<table>
<thead>
<tr>
<th>PI ratio</th>
<th>Mean mass of five beads (mg)</th>
<th>Theoretical loading in five beads (( \mu )g)</th>
<th>Actual loading in five beads (( \mu )g)</th>
<th>Loading efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>200:1</td>
<td>18-68 ± 0-19</td>
<td>39</td>
<td>33 ± 3</td>
<td>85</td>
</tr>
<tr>
<td>133:1</td>
<td>19-88 ± 0-20</td>
<td>62</td>
<td>53 ± 7</td>
<td>85</td>
</tr>
<tr>
<td>80:1</td>
<td>19-44 ± 0-26</td>
<td>101</td>
<td>75 ± 7</td>
<td>74</td>
</tr>
</tbody>
</table>

†Ratio of PI in 100 ml solution used to make beads.

---

**Table 2** Comparison of body weight and 14-day measures of food and water taken and fluid voided in untreated non-diabetic and STZ-diabetic rats, and in STZ-diabetic rats administered PI beads (30 \( \mu \)g insulin) twice daily over 14 days (treated). \( n=6 \) in all groups

<table>
<thead>
<tr>
<th>Measure</th>
<th>Group</th>
<th>Day</th>
<th>2</th>
<th>4</th>
<th>6</th>
<th>8</th>
<th>10</th>
<th>12</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urine (ml/24 h)</strong></td>
<td>Non-diabetic (untreated)</td>
<td>12</td>
<td>±2</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (untreated)</td>
<td>50</td>
<td>±3*</td>
<td>±5*</td>
<td>±4*</td>
<td>±2*</td>
<td>±2*</td>
<td>±2*</td>
<td>±2*</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (treated)</td>
<td>39</td>
<td>±6†</td>
<td>±5†</td>
<td>±2†</td>
<td>±1†</td>
<td>±1†</td>
<td>±1†</td>
<td>±1†</td>
</tr>
<tr>
<td><strong>Water intake (ml/24 h)</strong></td>
<td>Non-diabetic (untreated)</td>
<td>23</td>
<td>±3</td>
<td>±3</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (untreated)</td>
<td>100</td>
<td>±7*</td>
<td>±5*</td>
<td>±3*</td>
<td>±9*</td>
<td>±9*</td>
<td>±9*</td>
<td>±9*</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (treated)</td>
<td>63</td>
<td>±7*</td>
<td>±9*</td>
<td>±1†</td>
<td>±6†</td>
<td>±6†</td>
<td>±6†</td>
<td>±6†</td>
</tr>
<tr>
<td><strong>Food intake (g/24 h)</strong></td>
<td>Non-diabetic (untreated)</td>
<td>26</td>
<td>±1</td>
<td>±3</td>
<td>±3</td>
<td>±3</td>
<td>±3</td>
<td>±3</td>
<td>±3</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (untreated)</td>
<td>24</td>
<td>±2</td>
<td>±2</td>
<td>±2</td>
<td>±2</td>
<td>±2</td>
<td>±2</td>
<td>±2</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (treated)</td>
<td>24</td>
<td>±3</td>
<td>±5</td>
<td>±1†</td>
<td>±2†</td>
<td>±2†</td>
<td>±2†</td>
<td>±2†</td>
</tr>
<tr>
<td><strong>Weight change (%)</strong></td>
<td>Non-diabetic (untreated)</td>
<td>+5</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
<td>±1</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (untreated)</td>
<td>−2</td>
<td>±1*</td>
<td>−3*</td>
<td>−1*</td>
<td>−2*</td>
<td>−2*</td>
<td>−2*</td>
<td>−2*</td>
</tr>
<tr>
<td></td>
<td>STZ-diabetic (treated)</td>
<td>−3</td>
<td>±1*</td>
<td>−5*</td>
<td>−1*</td>
<td>−3*</td>
<td>−2*</td>
<td>−2*</td>
<td>−2*</td>
</tr>
</tbody>
</table>

\( *P<0.05 \) compared with non-diabetic rats; \( †P<0.05 \) compared with respective STZ-diabetic untreated rats.
significantly differ from that of non-diabetic rats between days 6 and 10, although more water was taken during days 2–4 and days 12–14. Administration of PI beads significantly reduced the amount of water taken by the groups concerned throughout the 14-day period, compared with the amounts taken by untreated STZ-diabetic rats.

**Plasma insulin and glucose concentrations**

When compared with control non-diabetic rats, untreated STZ-diabetic rats exhibited significantly low plasma insulin concentrations (0·32 ± 0·03 ng/ml, compared with 2·60 ± 0·44 ng/ml, n=6 in both groups) and increased plasma glucose concentrations (25·84 ± 1·44 mmol/l compared with 10·72 ± 0·52 mmol/l) after 2 weeks (Fig. 1). Daily oral administration of PI beads once (30 µg insulin) resulted in a slight, but statistically insignificant increase in plasma insulin concentrations (0·45 ± 0·02 ng/ml) by comparison with untreated STZ-diabetic rats. However, this treatment was associated with a significant ($P>0·01$) reduction in plasma glucose concentrations (17·82 ± 2·98 mmol/l) in comparison with values in untreated STZ-diabetic rats. Administration, at 0900 h for 2 weeks, of two PI beads containing 30 µg active insulin twice daily and three PI beads once daily (46 µg active insulin) to STZ-diabetic rats increased plasma insulin concentrations (0·89 ± 0·09 ng/ml and 1·85 ± 0·26 ng/ml respectively), with a concomitant reduction in plasma glucose concentration (15·45 ± 1·63 mmol/ml and 10·56 ± 0·26 mmol/ml respectively) at 0900 h the next day.

**Pharmacokinetic parameters**

STZ-diabetic rats previously given two oral doses daily of two PI beads (30 µg insulin) at 0900 h and the same dose 8 h later (1700 h) were used for pharmacokinetic studies 16 h after the last dose, at 0900 h the next day. The plasma insulin concentration–time profiles and the pharmacokinetic parameters after the oral administration of PI beads (30 µg insulin) or s.c. insulin (30 µg) at 0900 h and similar doses 8 h later (1700 h) are shown in Fig. 2 and Table 3 respectively. The mean $C_{\text{max}}$ plasma insulin concentration value was achieved earlier when PI beads were administered, compared with results after s.c. insulin (Fig. 2). Plasma glucose concentrations in animals orally administered PI beads decreased significantly from the 2nd hour before increasing again before the second treatment (Fig. 2). However, significant decreases in plasma glucose after s.c. insulin were observed only after 6 h, whereas plasma glucose concentrations were always significantly greater between 1100 h and 1500 h compared with values in STZ-diabetic rats orally administered PI beads.

**Discussion**

In the present study, successful delivery of insulin from orally administered, insulin-loaded, amidated pectin hydrogel beads in STZ-diabetic rats was achieved, as assessed by increases in plasma insulin concentrations and associated reductions in plasma glucose concentrations. As the STZ used to induce diabetes selectively destroys or impairs insulin secretion by β cells of the pancreas (Grussner et al 1993), low plasma insulin concentrations found in untreated STZ-diabetic rats may be attributed to residual β cells of the pancreas. We prepared the insulin hydrogel beads by the gelation of a humilin (human insulin)-loaded pectin solution, as there is no difference in biological potency of human insulin and animal insulins (Brogden & Heel 1987, Heinemann & Ritcher 1993). Studies have shown that s.c. administration of humilin reduces blood glucose in rats (Shaw & Su 1991) and non-obese mice (Sai et al 1996). The doses of insulin (0·10 µg/kg once or twice,
and 0.15 µg/kg once) chosen in this study are lower than those previously used in human studies (6.25–17.86 µg/kg; Peacey et al. 1999, Simpson & Spencer 1999).

Previous observations suggest that insulin absorption in the intestinal tract occurs in the ileum, large intestine and the jejunum (Kimura et al. 1996). The appearance of significant plasma concentrations of insulin 2–4 h after oral administration of PI beads, with a decrease in plasma glucose concentrations, in STZ-diabetic rats suggests the jejunum (Kimura et al. 1996). The appearance of significant plasma concentrations of insulin 2–4 h after oral administration of PI beads, with a decrease in plasma glucose concentrations, in STZ-diabetic rats suggests that previously used in human studies (6/p5dosing. Each point represents the mean ± S.E.M. of six animals.

![Graph](image)

**Figure 2** Comparison of the effects of oral administration of PI beads (30 µg insulin; ▲) and s.c. insulin (30 µg; ▄) at 0900 h and 1700 h on plasma glucose (a) and plasma insulin (b) concentration profiles in STZ-diabetic rats previously orally administered PI beads (30 µg insulin) twice daily for 14 days. Arrows indicate times of dosing. Each point represents the mean ± S.E.M. of six animals.

Table 3 Pharmacokinetic parameters after oral administration of PI beads (30 µg insulin) and s.c. insulin (30 µg) to male Sprague–Dawley rats

<table>
<thead>
<tr>
<th>Dosage form</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (mmol/l)</th>
<th>T&lt;sub&gt;p&lt;/sub&gt; (h)</th>
<th>AUC (mmol/l per h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral PI beads (30 µg)</td>
<td>4.88 ± 0.06</td>
<td>2</td>
<td>39.51</td>
</tr>
<tr>
<td>S.c. insulin (30 µg)</td>
<td>2.42 ± 0.22</td>
<td>18</td>
<td>33.89</td>
</tr>
</tbody>
</table>

release of insulin from the beads and its intestinal absorption in these regions. This not only coincides with transit time in the rat, but agrees with observations of peak plasma insulin concentrations and hypoglycaemic effects within 1.5–2 h after oral administration of insulin coated with polymers cross-linked with azoaromatic groups, to rats and diabetic dogs (Saffran et al. 1986, 1991). Conceivably, insulin released will have some contact with luminal contents before absorption, and thus luminal proteolysis by microbial proteases has to be reduced. The present study did not investigate the influence of protease inhibitors, absorption enhancers and polymeric coatings, which can significantly improve bioavailability. However, carbopol polymers have been used to reduce the colonic proteolysis of insulin, enhancing pharmacological effects of the peptide in rats (Bai et al. 1995).

The present findings cannot explain why administration of PI beads delivering a single 46 µg dosage of insulin appears to be more efficient than the two doses delivering 30 µg given at 0900 h and 1700 h. Perhaps the transit time of individual beads and enzymatic breakdown of the beads and the influence of food contributed to these observations. Interestingly, Saffran et al. (1991) also could not find dose-related changes in plasma insulin concentrations after oral administration of various doses of insulin in azopolymer-coated capsules.

The pharmacokinetic parameters after oral dosing and s.c. injections suggest that C<sub>max</sub> plasma insulin concentration is attained sooner when the oral route is used (Fig. 2, Table 3). If insulin were released from the PI beads in the distal parts of the intestine, then the mean C<sub>max</sub> plasma insulin concentration should be reached much later by comparison with s.c. insulin. We suggest that insulin was initially released as a bolus, as a result of solubilization of pectin gels by excess hydroxyl ions (Munjeri et al. 1997), and also because of increases in electrostatic repulsions between pectin molecules resulting from hypo-osmotic conditions (Cunha et al. 1997). The release of insulin from pectin hydrogel beads is also enhanced by the breakdown of pectin by colonic bacteria. The decrease in plasma glucose concentrations 6 h after s.c. injection of humilin agrees with previous observations (Berger & Rodbard 1998).

Food consumption was reduced in STZ-diabetic rats between 6 and 10 days after they received PI beads. This observation cannot be explained by the results from the present study, but may be related to the stage of diabetes development when insulin may modulate food intake. A reduction in food intake has been reported after intravenous infusion of insulin in Zucker rats (Ikeda et al. 1986, Alemzadeh & Holshouser 1999). The presence of insulin receptors on the luminal side of the intestinal mucosa (Pillow et al. 1985) suggests that insulin may modulate intestinal function in some way.

In conclusion, data from this study suggest that an insulin-loaded, amidated pectin hydrogel bead formulation...
not only produces sustained release of insulin, but may also reduce plasma glucose concentration in diabetes mellitus.

Acknowledgements

Professor C T Musabayane was funded by the University of Zimbabwe Research Board (YYH010/3580). The authors are grateful for the technical support from Messrs P Hodza, A Musvibe and J Wenyika.

References


Heinemann I & Ritcher RC 1993 Clinical pharmacology of human insulin. Diabetics Care 16 90–100.


Received 12 April 1999
Accepted 11 August 1999